A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Bibliographic Details
Main Author:	Khan, Muidul Hasan
Other Authors:	Khair, Nishat Zareen
Format:	Thesis
Language:	English
Published:	Brac University 2024
Subjects:	Bruton’s Tyrosine Kinase B-cell receptor signaling Chronic lymphocytic leukemia Cancer BTK Inhibitors BTKi Resistance Lymphocytic leukemia Cancer > Treatment
Online Access:	http://hdl.handle.net/10361/23233

id	10361-23233
record_format	dspace
spelling	10361-232332024-06-09T21:00:36Z A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer Khan, Muidul Hasan Khair, Nishat Zareen School of Pharmacy, Brac University Bruton’s Tyrosine Kinase B-cell receptor signaling Chronic lymphocytic leukemia Cancer BTK Inhibitors BTKi Resistance Lymphocytic leukemia Cancer--Treatment This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of thesis. Includes bibliographical references (pages 26-39). In many B cell malignancies, Bruton's tyrosine kinase (BTK), a non-receptor kinase, plays a significant role in oncogenic signaling that is essential for the proliferation and survival of leukemic cells. BTK works as a transducer in B cell receptor and other cell surface receptors. Hence they can drive the proliferation of cancerous cells through the B cell receptor (BCR) signaling pathway. So, BTK inhibitors can play an important role in the management of such malignant tumors. This review is comprised of an updated compilation of drugs that bind to BTK and make them unable to play their role in the BCR signaling pathway. BTK inhibitors that are available in the market are, Ibrutinib, Acalbrutinib, Zanubrutinib, Tirabrutinib, Orelabrutinib and Pirtobrutinib. Most of these drugs are not highly selective to BTK and can cause resistance. So, to overcome the problems caused by the existing BTK inhibitors, new drugs are needed to be developed. Some promising drugs are currently under clinical trial which may overcome these problems. They are Spebrutinib, Evobrutinib, Vecabrutinib and Fenebrutinib. Muidul Hasan Khan B. Pharmacy 2024-06-09T04:22:49Z 2024-06-09T04:22:49Z ©2023 2023 Thesis ID: 19346066 http://hdl.handle.net/10361/23233 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 51 pages application/pdf Brac University
institution	Brac University
collection	Institutional Repository
language	English
topic	Bruton’s Tyrosine Kinase B-cell receptor signaling Chronic lymphocytic leukemia Cancer BTK Inhibitors BTKi Resistance Lymphocytic leukemia Cancer--Treatment
spellingShingle	Bruton’s Tyrosine Kinase B-cell receptor signaling Chronic lymphocytic leukemia Cancer BTK Inhibitors BTKi Resistance Lymphocytic leukemia Cancer--Treatment Khan, Muidul Hasan A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
description	This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
author2	Khair, Nishat Zareen
author_facet	Khair, Nishat Zareen Khan, Muidul Hasan
format	Thesis
author	Khan, Muidul Hasan
author_sort	Khan, Muidul Hasan
title	A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
title_short	A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
title_full	A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
title_fullStr	A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
title_full_unstemmed	A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
title_sort	review on bruton's tyrosine kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
publisher	Brac University
publishDate	2024
url	http://hdl.handle.net/10361/23233
work_keys_str_mv	AT khanmuidulhasan areviewonbrutonstyrosinekinaseinhibitorstooutlinethescopesoffurtheradvancementsinthetreatmentofcancer AT khanmuidulhasan reviewonbrutonstyrosinekinaseinhibitorstooutlinethescopesoffurtheradvancementsinthetreatmentofcancer
_version_	1814307019082956800

A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer

Similar Items